SiteOne Therapeutics, Inc. logo

SiteOne Therapeutics, Inc.

SiteOne Therapeutics is dedicated to developing novel pain therapeutics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing drugs, such as opioids. Given the critical role that NaV1.7 plays in the generation and conduction of pain signals, combined with the urgent need for new, non-opioid pain therapies, SiteOne is focused on advancing its lead products to serve patients that suffer from moderate to severe pain.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.siteonetherapeutics.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
203 Enterprise Blvd. Suite 3, MT 59718
Bozeman
United States
Email
Contact Number
+1 406-577-2173

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/siteone-therapeutics-inc.” connections=”true” suffix=””]

Its technology is based on highly potent and selective voltage-gated sodium ion channel inhibitors patterned after naturally occurring small molecule marine guanidinium toxins (GTXs) that very specifically target the sodium channel (Nav) protein family.

SiteOne Therapeutics and Amgen entered into research and development agreement for the development of Na?1.7 inhibitors.SiteOne also received $15 million series B round of financing, led by Amgen and joined by founding investors Next Frontier Capital, 2M Companies Inc., Mission Bay Capital, Sears Capital Management, Biobrit LLC, and Z Investments.

In July 2015, SiteOne Therapeutics Secures Investment from Bozeman-based Next Frontier Capital to advance its platform of non-opioid therapeutics for acute and chronic pain.

SiteOne was awarded $1.4 Mn, two-year, Phase II SBIR grant from the National Institutes of Health and also secures $1.5 Mn of initial round of equity financing for the development of oral inhibitors Nav1.7 as therapeutics for acute and chronic pain.